Table 1

Demographics and patient characteristics

CharacteristicLow renal involvement (LRI)* pretreatmentHigh renal involvement (HRI)* pretreatmentTotalp Value (LRI vs HRI)
Patients enrolled (men/women)31, 119, 152 (50, 2)
Age at treatment initiation (years)<0.001
 Mean (SD)25.3 (7.7)37.7 (8.7)30.1 (10.0)
 Median (range)22.5 (16.5–44.7)36.6 (26.3–62.2)29.4 (16.5–62.2)
Age at last Registry follow-up (years)<0.001
 Mean (SD)37.2 (7.6)48.7 (8.2)41.6 (9.6)
 Median (range)34.8 (26.8–53.5)47.3 (38.5–73.8)40.0 (26.8–73.8)
Follow-up time (years)0.659
 Mean (SD)8.7 (2.5)8.4 (2.5)8.6 (2.5)
 Median (range)10.0 (1.4–10.5)10.0 (4.5–10.5)10.0 (1.4–10.5)
UPCR (g/g) at baseline<0.001
 Mean (SD)0.2 (0.1)1.3 (0.9)0.6 (0.8)
 Median (range)0.1 (0–0.5)1.1 (0.4–3.6)0.3 (0–3.6)
eGFR (mL/min/1.73 m2) at baseline<0.001
 Mean (SD)126.0 (18.71)101.6 (22.78)116.6 (23.44)
 Median (range)127.7 (73.1–170.0)108.9 (49.1–138.5)118.8 (49.1–170.0)
LPWT at baseline (mm)0.005
 Mean (SD)9.8 (1.66)11.9 (2.67)10.6 (2.31)
 Median (range)10.0 (7.0–13.0)11.0 (9.0–18.9)10.4 (7.0–18.9)
IVST (mm) at baseline0.007
 Mean (SD)10.0 (1.73)11.9 (2.63)10.7 (2.31)
 Median (range)10.0 (7.0–16.0)11.0 (9.0–20.0)10.3 (7.0–20.0)
Plasma GL-3 (μg/mL) at baseline0.696
 Mean (SD)9.5 (3.02)9.9 (2.66)9.7 (2.86)
 Median (range)9.5 (3.6–16.7)9.6 (4.7–14.5)9.5 (3.6–16.7)
  • *LRI=UPCR ≤0.5 g/g and <50% sclerotic glomeruli; HRI=UPCR >0.5 g/g or ≥50% sclerotic glomeruli.

  • N=52 for all parameters, except for LPWT and IVST (both N=50), and UPCR (N=47).

  • eGFR, estimated glomerular filtration rate; GL-3, globotriaosylceramide; IVST, interventricular septum thickness; LPWT, left ventricular posterior wall thickness; UPCR, urine protein to creatinine ratio.